As previously observed with HDAC inhibitor treatment, shRNA-mediated depletion of HDAC3 caused a significant (approximately 4-fold) up-regulation of the DNA damage marker γ-H2AX in cancer cells (Figure 4A). The gene discussed is HDAC9; the disease is cancer.